What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Surgery
- Antibiotics
Jose A. Vazquez focuses on Internal medicine, Surgery, Mycosis, Fluconazole and Adverse effect.
His studies deal with areas such as Gastroenterology, Dalbavancin and Bacteremia as well as Internal medicine.
His research integrates issues of Antibiotics, Candida krusei and Cilastatin in his study of Surgery.
As part of one scientific family, he deals mainly with the area of Mycosis, narrowing it down to issues related to the Candida glabrata, and often Corpus albicans.
His Fluconazole research incorporates themes from Amphotericin B, Posaconazole, Pharmacotherapy and Esophageal candidiasis.
His work carried out in the field of Adverse effect brings together such families of science as Caspofungin and Micafungin.
His most cited work include:
- Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America (1207 citations)
- Executive Summary: Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America (840 citations)
- Candida glabrata: review of epidemiology, pathogenesis, and clinical disease with comparison to C. albicans. (742 citations)
What are the main themes of his work throughout his whole career to date?
His primary areas of investigation include Internal medicine, Microbiology, Fluconazole, Mycosis and Surgery.
His Internal medicine study deals with Gastroenterology intersecting with Candida krusei.
His Fluconazole research is multidisciplinary, incorporating elements of Amphotericin B, Azole, Itraconazole and Esophageal candidiasis.
His study looks at the relationship between Esophageal candidiasis and topics such as Intensive care medicine, which overlap with Epidemiology, Invasive candidiasis, Prospective cohort study and Linezolid.
His biological study spans a wide range of topics, including Regimen, Neutropenia, Chemotherapy and Intensive care unit.
Jose A. Vazquez works mostly in the field of Candida albicans, limiting it down to topics relating to Immunology and, in certain cases, Vaginitis and Vagina.
He most often published in these fields:
- Internal medicine (34.44%)
- Microbiology (37.78%)
- Fluconazole (30.56%)
What were the highlights of his more recent work (between 2017-2021)?
- Internal medicine (34.44%)
- Intensive care medicine (17.22%)
- Invasive candidiasis (5.00%)
In recent papers he was focusing on the following fields of study:
Jose A. Vazquez mainly investigates Internal medicine, Intensive care medicine, Invasive candidiasis, Adverse effect and Randomized controlled trial.
His studies deal with areas such as Echinocandin and Caspofungin as well as Internal medicine.
He has researched Intensive care medicine in several fields, including Invasive fungal disease, Cancer, Abdominal Infection and Peripherally inserted central catheter.
His work on Open label study as part of general Adverse effect research is frequently linked to New england, bridging the gap between disciplines.
In general Randomized controlled trial study, his work on Clinical endpoint often relates to the realm of Carbapenem-resistant enterobacteriaceae, thereby connecting several areas of interest.
The concepts of his Fluconazole study are interwoven with issues in Amphotericin B, Voriconazole and Confidence interval.
Between 2017 and 2021, his most popular works were:
- Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium (285 citations)
- Effect and Safety of Meropenem–Vaborbactam versus Best-Available Therapy in Patients with Carbapenem-Resistant Enterobacteriaceae Infections: The TANGO II Randomized Clinical Trial (146 citations)
- Identification of COVID-19 can be quicker through artificial intelligence framework using a mobile phone-based survey when cities and towns are under quarantine. (127 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Antibiotics
- Surgery
His scientific interests lie mostly in Internal medicine, Clinical trial, Intensive care medicine, Adverse effect and Randomized controlled trial.
His Internal medicine research integrates issues from Fluconazole, Candida tropicalis, Candida krusei and Candida albicans.
His Clinical trial research is multidisciplinary, relying on both Amphotericin B, Voriconazole, Caspofungin, Micafungin and Confidence interval.
His research integrates issues of Cystic fibrosis, Disease and Scedosporium in his study of Intensive care medicine.
His Adverse effect study integrates concerns from other disciplines, such as Bacteremia, Tigecycline, Clinical endpoint and Levofloxacin.
His Randomized controlled trial study combines topics in areas such as Mortality rate and Bacterial pneumonia.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
